# A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease

> **NCT04597697** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 25 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin icodec

## Key facts

- **NCT ID:** NCT04597697
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-03-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04597697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04597697, "A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04597697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*